NASDAQ:INCYIncyte Stock Price, Forecast & News

Incyte's stock was trading at $71.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INCY shares have increased by 46.3% and is now trading at $105.18. View which stocks have been most impacted by Coronavirus.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Incyte.

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Incyte.

Incyte Co. (NASDAQ:INCY) posted its earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($2.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by $3.17. The biopharmaceutical company had revenue of $568.51 million for the quarter, compared to the consensus estimate of $553.24 million. Incyte had a negative return on equity of 12.81% and a negative net margin of 16.87%. The business's quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.62 earnings per share. View Incyte's earnings history.

23 brokers have issued 12 month price objectives for Incyte's shares. Their forecasts range from $79.00 to $124.00. On average, they anticipate Incyte's stock price to reach $100.65 in the next year. This suggests that the stock has a possible downside of 4.3%. View analysts' price targets for Incyte.

News headlines about INCY stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Incyte earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Incyte.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Micron Technology (MU), Array Biopharma (ARRY) and Celgene (CELG).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.04%), DNB Asset Management AS (0.01%), Envestnet Asset Management Inc. (0.01%), Patton Fund Management Inc. (0.00%), Symphony Financial Ltd. Co. (0.00%) and Exane Derivatives (0.00%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing. View institutional ownership trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including Patton Fund Management Inc., Envestnet Asset Management Inc., and Exane Derivatives. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon, and Yao Wenqing. View insider buying and selling activity for Incyte.

INCY stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, DNB Asset Management AS, Symphony Financial Ltd. Co., and Ellevest Inc.. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Jean Jacques Bienaime. View insider buying and selling activity for Incyte.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $105.18.

Incyte has a market capitalization of $22.86 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

The official website for Incyte is www.incyte.com.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]